ADGRL1-IN-1
ADGRL1-IN-1 is a ADGRL1 inhibitor. ADGRL1-IN-1 activates the GSK3β-STAT1 signaling axis. ADGRL1-IN-1 induces anti-tumor immunity in a CT26 colorectal cancer mouse model. ADGRL1-IN-1 can be used in studies related to colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 693829-95-7
- Formula: C16H9BrF3NO
- Molecular Weight:368.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
GSK-3β |
STAT1 |
In Vitro
ADGRL1-IN-1 (Compound 2) (15 mM) binds directly to ADGRL1 in CT26 cells, as evidenced by its ability to protect the receptor from protease degradation at a concentration of 15 mM[1].
ADGRL1-IN-1 activates the GSK3β-STAT1 axis in CT26 cells and induces BMDC activation via factors secreted by CT26 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 693829-95-7
-
Molecular Weight 368.15
-
Formula C16H9BrF3NO
-
SMILES
FC(C1=CN=C(OC2=CC=C3C=CC=CC3=C2Br)C=C1)(F)F
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)